-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
The main purpose of this study is to study the effectiveness and safety of slulimumab combined with chemotherapy in ES-SCLC patients who have not received previous treatment
Professor Cheng Ying, the main investigator of the NCT04063163 study, the director of the Jilin Provincial Cancer Center, the director of the Jilin Provincial Lung Cancer Diagnosis and Treatment Center, and the director of the Malignant Tumor Clinical Research Integrated Diagnosis and Treatment Center of Jilin Provincial Tumor Hospital, said : "I am very excited to see the widespread use of slulimumab.
Professor Wang Jie from the Chinese Academy of Medical Sciences Tumor Hospital, IDMC chairman of the NCT04063163 study , said : “SCLC is a type of lung cancer with strong aggressiveness and poor prognosis.
Another IDMC member, Professor Giorgio Scagliotti from the Medical Oncology Center of the University of Turin, Italy , said : “The global clinical options for SCLC are very limited, especially anti-PD-1 monoclonal antibody-related treatment options.
Mr.
SCLC is highly malignant, and existing treatments are limited
According to GLOBOCAN data, lung cancer is the second most common type of cancer in the world.
In the past 20 years, etoposide combined with carboplatin or cisplatin has been the standard first-line treatment for ES-SCLC patients.
Focusing on patient needs, covering first-line treatments for all types of lung cancer
Focusing on the differentiated development strategy of "Combo+Global" (combination therapy + internationalization), slulimumab has obtained clinical trial licenses in China, the United States, the European Union and other countries and regions, and currently a total of 10 tumor immunotherapy clinical trials are carried out.
Based on slulimumab, the company focuses on lung cancer and gastrointestinal tumors based on the characteristics of global and Chinese cancer patients
